OFI Invest Asset Management Reduces Stock Position in Merck & Co., Inc. $MRK

OFI Invest Asset Management lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 705,885 shares of the company’s stock after selling 27,934 shares during the quarter. Merck & Co., Inc. accounts for 0.9% of OFI Invest Asset Management’s portfolio, making the stock its 22nd largest position. OFI Invest Asset Management’s holdings in Merck & Co., Inc. were worth $74,301,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MRK. Brighton Jones LLC grew its stake in Merck & Co., Inc. by 29.5% during the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC grew its stake in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after purchasing an additional 3,941 shares during the last quarter. Sentinus LLC lifted its holdings in shares of Merck & Co., Inc. by 5.6% in the 2nd quarter. Sentinus LLC now owns 3,745 shares of the company’s stock valued at $296,000 after buying an additional 199 shares during the period. BCS Private Wealth Management Inc. acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at about $218,000. Finally, Stamos Capital Partners L.P. lifted its holdings in shares of Merck & Co., Inc. by 98.6% in the 2nd quarter. Stamos Capital Partners L.P. now owns 226,905 shares of the company’s stock valued at $17,962,000 after buying an additional 112,671 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck launched a cash tender offer to buy Terns Pharmaceuticals, accelerating an acquisition that expands its oncology and hematology pipeline ahead of patent expiries for key products — a strategic move that can support future revenue. Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
• Positive Sentiment: JPMorgan and other analysts have raised price targets / reiterated Overweight views on MRK, signaling institutional confidence that Merck shares still have upside — a catalyst for buying interest. JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock
• Positive Sentiment: Merck’s recent quarterly results beat estimates, revenue grew year-over-year and the company set FY2026 EPS guidance — underpinning valuation and investor confidence in near-term fundamentals. Strong Results Lifted Merck & Co (MRK) in Q4
• Positive Sentiment: Merck is highlighted among consistent dividend stocks, which can attract income-focused and defensive investors amid market uncertainty. Is Merck & Co. (MRK) One of the Best Consistent Dividend Stocks to Buy Right Now?
• Neutral Sentiment: Merck lowered its offer price for Terns after reviewing trial data, a detail that changes deal economics and signals the firm is calibrating cost vs. risk — ambiguous for MRK shareholders (lower cash outlay vs. potential pipeline concerns). Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
• Neutral Sentiment: Coverage pieces are reassessing Merck’s valuation after strong price momentum; momentum supports higher multiples, but some analysts flag S&P 500 reweighting and valuation headwinds. Assessing Merck (MRK) Valuation After Strong Recent Share Price Momentum
• Neutral Sentiment: Analysis explains the Terns deal’s role in Merck’s pipeline and how it could affect S&P 500 valuation exposure — useful context but not an immediate share-mover. Merck’s (NYSE:MRK) Terns Deal And S&P 500 Valuation Impact Explained
• Negative Sentiment: Some intraday weakness was reported recently as the broader market improved — a reminder that short-term pullbacks can occur even with positive headlines. Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
• Negative Sentiment: Commentary questioning whether Merck is overbought warns of near-term valuation risk after a big run — a potential headwind for momentum traders. Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the completion of the transaction, the executive vice president owned 68,916 shares of the company’s stock, valued at $8,211,341.40. This represents a 63.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Caroline Litchfield sold 41,997 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the transaction, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at $10,787,865.12. The trade was a 31.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on MRK shares. Cantor Fitzgerald boosted their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. TD Cowen boosted their price objective on Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Wells Fargo & Company boosted their price objective on Merck & Co., Inc. from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, Guggenheim boosted their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $127.59.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $123.25 on Thursday. The stock has a market cap of $304.73 billion, a PE ratio of 16.93, a price-to-earnings-growth ratio of 2.44 and a beta of 0.26. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The business has a 50-day simple moving average of $118.54 and a 200-day simple moving average of $104.06.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.Merck & Co., Inc.’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were issued a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.